NCT07652931 · NOT YET RECRUITING
Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns
This study uses artificial intelligence to analyze brain scans, blood tests, eye imaging, and cognitive tests to spot early Alzheimer's biology in people who feel their memory is slipping but still test normally. Those flagged as high risk then receive a combination of brain stimulation (TMS), cognitive training, exercise, and lifestyle coaching. Phase NA means this is an observational and feasibility study — not a standard drug trial and not yet proven to change outcomes.
You may qualify if
- Diagnosis of Subjective Cognitive Decline (SCD) according to international diagnostic criteria (Jessen et al., 2014).
- Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event.
- Normal age-, gender-, and education-adjusted performance on standardized cognitive tests used to classify mild cognitive impairment (MCI) or prodromal AD.
- Age greater than or equal to 40 years.
- Native Italian Speaker.
- Stable pharmacological treatment for at least 4 weeks prior to enrollment.
- Provision of oral and written informed consent to study participation.
You're excluded if
- Presence of MCI, prodromal AD, or dementia.
- Any major systemic, psychiatric, or neurological disturbance.
- Medical conditions or substance abuse that could interfere with cognition.
- Pacemaker and/or other implanted neurostimulation devices in the head/neck district.
- Contraindications to undergoing MRI examination.
- Brain damage at routine MRI, including extensive cerebrovascular disorders.
- Traumatic or surgical wounds that could determine a risk of infection at the site of non-invasive stimulation.
- Scalp alterations that could determine the spread of excessive current from the device.
- Known history of epilepsy (due to small risk of seizure induction from rTMS in epileptic patients).
- Denial of oral and written informed consent to study participation.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-06-17